Study with apalutamide in patients with prostate cancer in whom the prostate has been removed who are at high risk of disease recurrence
- Conditions
- High risk adenocarcinoma of the prostate after radical prostatectomy (RPE)MedDRA version: 20.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2018-004329-10-DE
- Lead Sponsor
- Westfälische Wilhelms-Universität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Recht u. Drittmittel
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- Male
- Target Recruitment
- 190
1. Signed informed consent form (ICF)
2. Men = 18 years of age
3. Patients with histologically confirmed adenocarcinoma of the prostate after radical prostatectomy
4. Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1
5. Exclusion of metastatic disease by CT-scan of abdomen (MRI of abdomen is possible)
and bone scan prior to study inclusion. A PSMA PET-CT/MRI is possible. In this case it has to be done with a diagnostic CT/MRI with contrast media and not with a low dose CT-scan only. In case PSMA-PET imaging has been done, a bone scan can be omitted. CT/MRI, and bone-scan imaging or PSMA PET-CT/MRI administered =12 weeks before RPE may be used for screening
6. Patients after RPE must meet the d’Amico criteria for high risk of disease recurrence (T-stage and Gleason-score determined after radical prostatectomy) i.e. 1 of the following after RPE: 1) Gleason score =8, any T-stage, any iPSA or 2) Gleason score 6 or 7, any iPSA and =pT3 or 3) iPSA >20 ng/ml, any Gleason score, any T-stage.
7. Patients have to have recovered from radical prostatectomy within eight weeks to be able to take part in the study
8. PSA must have declined below 0.2 ng/ml prior to randomization
9. Adequate hematologic, hepatic, and renal function:
• Hematologic
i) Haemoglobin = 9.0 g/dL independent of transfusions
ii) Neutrophils = 1.5 Ths./µL
• Hepatic
i) Total Bilirubin =< 1.5X upper limit of normal (ULN) [except for subjects with documented Gilbert’s disease in which case total bilirubin not to exceed 10X ULN]
ii) Alanine (ALT) and aspartate (AST) aminotransferase =< 2.5X ULN
• Renal:
i) Serum creatinine <1.5X ULN or calculated creatinine clearance = 50 mL/min
ii) Serum potassium = 3.5 mM
iii) Serum albumin = 3.0 g/dL
10. Ability to swallow study medication tablets
11. In case of apalutamide treatment: Agrees to use a condom and another highly effective method of birth control if he is having sex with a woman of childbearing potential or to use a condom if he is having sex with a woman who is pregnant
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 95
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 95
1. Any chronic medical condition requiring a higher dose of corticosteroid than 10mg prednisone/prednisolone q.d.
2. Prior cytotoxic chemotherapy or biologic therapy for the treatment of prostate cancer
3. Prior or current treatment of prostate cancer with apalutamide, enzalutamide, darolutamide, or other investigational agents targeting the androgen receptor
4. Prior therapy with Sipuleucel-T or other vaccination or immunogenic therapy for the treatment of prostate cancer
5. Prior treatment with abiraterone acetate or other androgen synthesis inhibitors (e. g. ketoconazole, TAK700, TOK001)
6. Use of 5-a reductase inhibitors (eg, dutasteride, finasteride) =4 weeks prior to randomization
7. Prior surgical castration or medical castration using LHRH-Agonists or GnRH-Antagonists
8. Prior or current radiation or radionuclide (including radium-223 dichloride) therapy for treatment of prostate cancer (adjuvant radiation of the prostate bed without involvement of the regional lymph node template as by standard of care in case of positive surgical margins (R1) is allowed)
9. Prior or current systemic treatment with an azole drug (e.g. fluconazole, itraconazole) within 4 weeks of Cycle 1, Day 1
10. Any lymph node or distant metastasis
11. History of seizures or condition that may predispose to seizure (including, but not limited to prior stroke, transient ischemic attack or loss of consciousness =1 year prior to randomization; brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect).
12. Current or prior treatment with anti-epileptic medications for the treatment of seizures
13. Management of cardiovascular risk factors, such as hypertension, diabetes or dyslipidaemia should be optimised as per standard of care before treatment with apalutamide will be initiated
13.1. Uncontrolled hypertension (systolic BP =140 mmHg or diastolic BP =90 mmHg. For patients with relevant comorbidities (e.g. diabetes) systolic BP =130 mmHg or diastolic BP =80 mmHg). Patients with a history of hypertension are allowed provided that blood pressure is controlled by anti-hypertensive treatment
13.2. Patients with uncontrolled diabetes defined as HbA1c =7.5%
13.3. Patients with a dyslipidemia defined as LDL cholesterol >100 mg/dl. For patients with a dyslipidemia defined as LDL cholesterol >100 mg/dl and SCORE-value of 1-5%: In case of a SCORE-value of <1% a LDL cholesterol level of up to 115 mg/dl is acceptable. In case of increased LDL cholesterol above these values a statin-therapy can be initiated and a rescreening within 4 weeks is possible
13.4. Cardiovascular risk assessment via an appropriate score (e.g. the SCORE-Chart for the European high/low risk score from the European Society of Cardiology) and = borderline risk i.e. 10% of developing cardiovascular events within 10 years without prior cardiovascular disease
14. Active or symptomatic viral hepatitis or chronic liver disease or HIV
15. History of pituitary or adrenal dysfunction
16. Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 12 months, severe or unstable angina, or New York Heart Association (NYHA) Class II-IV heart disease or cardiac ejection fraction measurement of <50% at baseline, or clinically relevant pelvic lymphocele after radical prostatectomy as evaluated by clinical examination and/or pelvic ultrasound (if a risk is present, patients may be al
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method